Congrats on the excellent quarter, for sure. The first half of this fiscal year has gone well as we've executed to our commitments and delivered better than expected results. Okay. And then we would expect to continue that improvement into the back-half. Like I just mentioned, we're out there working with physicians, and their offices and hospitals. We have said that we expect to deliver 40 basis points of op margin improvement this fiscal year, and that hasn't changed. Josh Jennings -- Cowen & Company -- Analyst. Thank you. Medtronic has been a long time member of the Santa Rosa Community, and while our operations aren't currently affected, our thoughts are with those heroes battling these terrible blazes and the people affected, including some of our employees. We are expanding margins and at the same time investing more in research and development to enhance our pipeline, resulting in first quarter R&D expense growing 100 basis points faster than revenue, as we focus on driving long-term value. So, please read that into what we're saying here and we expect to execute and deliver and we feel really good about this business, both from a top line perspective as well as margin expansion program perspective. And we are only in the beginning of that journey and we expect that this product will continue to innovate over time and we will be leading that innovation, sort of, road map. And I have one follow-up on CVG. Several of our plants ran at less than full capacity, resulting in a larger period expense of our fixed overhead costs, and a decline in our gross margin as we expected. We are working to leverage our breadth in many areas, from global manufacturing and technology sharing, to our clinical and regulatory expertise, shared services and global distribution. (FSLY) (ticker: FSLY) late Wednesday warned that September quarter revenues would fall short of its original guidance by a few million dollars—they now expect $70 million to $71 million, down from a previously estimate of $73.5 million to $75.5 million—due largely to a reduction in revenue from TikTok, the company’s largest client. In other businesses, we're seeing the benefit of new product launches, as our pipeline kicks in across the company. And we've got diversified positions in high-growth market segments and that's our priority, to maintain that, to continue to grow that and add to that in terms of tuck-in acquisitions. And then I've been working closely with the group -- the four group leaders, including Sean and Brett that are new to it, on a capital allocation strategy that moves to the highest-growth segments that isn't done necessarily at the group level, it's done at a more granular level. And in the hospitals, and I just talked to another hospital's CEO on Friday. On the first one, regarding market share, you're asking why the focus, what's changed. I can tell you, I'm very impressed. And when you have an organization like RTG that, with the resources and the capabilities, if you can get some of the -- an organization like that focused on something like this, with this kind of momentum, it's going to continue. It's a clear focus in our quarterly business reviews. And then Karen, just kind of related question. So we're seeing an installed base increase and we're pleased with that. And importantly, the recharger doesn't need to be perfectly aligned for a successful charge. And as you know, we're competing against a lot of focused, smaller focused companies, not just here, but in China and other places around the world. And overtime, we're very device centric. All of these adjustment details can be found in the reconciliation tables included with our earnings press release. R&D offer income statement, these creative third party partnerships like Blackstone, which have a very good return on them, are also something we want to use, and are inorganic. Like I mentioned, DBS, we have the directional lead system coming out. Our enterprise excellence initiatives, where we leverage our size and scale to improve our effectiveness and efficiency, continued to benefit our P&L, particularly on the SG&A line. Over the medium and longer term, we do see this getting back to mid-single to high single-digit growth in the SCS space. And so the -- what's converting -- you know, what's converting is two drivers. As a reminder, this program is still just in its early stages and is expected to drive sustained cost savings, while also allowing for greater reinvestments in R&D over the next several years. We now have over 97,000 trained active users of our 670G system. You have the pipeline, which we've talked about. Is that accelerating this process to the point where we might see the bulk of that benefit here in the first year versus the three or four years that it would have taken, just based on the timing of warranty expirations? As you know, this business -- that original facility was under a warning letter, so we're being very careful about making sure we have very robust validation and verification activities taking place, which took some of our manufacturing capacity offline while we did that work. And I would just add Rick that on the second quarter, in particular, we did say that we expect 5.5% to 6% organic growth in the second quarter, which is higher than the other quarters, given the comparison. Honestly, when we had our recent officers meeting, we spent the entire day talking about how we could improve free cash flow. Well, on the innovation side, I mean, like I said, we feel like we've got a great pipeline, the best we've had, and it's coming to fruition now and we've got more out there in the medium and long-term. And importantly, again, with the spiral design process, we're doing it in delivering a system that's based on the input and the features that our surgeons want most. And like we've talked about our pipeline is the best it's been in a long-time. I just think, look, neuromodulation is a big growth opportunity for the industry, for the company, and I think it's going to have a huge impact on patients. And then secondly, Mike, on the TAVR side of things, you mentioned a little bit of impact competitively. With that let's now open the phone calls up for Q&A. In DBS and Pelvic Health, while we lost share in the quarter, we're very bullish on where we're headed. * Intuitive Surgical (NASDAQ: ISRG) shares are trading lower after the company reported its Q3 da Vinci shipments decreased 29% year over year and its Q3 revenue decreased 4% year over year. Great. Market data powered by FactSet and Web Financial Group. Thanks. First, a few logistical comments. [Operator instructions] I would now like to hand the conference over to Ryan Weispfenning, vice president, investor relations. So, there's a lot more to go into there, but some of the things that are on the pipeline like already in that's a multibillion dollar opportunity there. And so, having our offerings be smarter and self-learning, and our offerings providing a lot of data and insights in addition to therapy back to our customers, I think this is an area that that this is going to take some time. Butterfield & Son (NTB)Butterfield is a small-cap banking firm based in Bermuda and providing a full range of services to customers on the island – and on the Caymans, the Bahamas, and the Channel Islands, as well as Singapore, Switzerland, and the UK. I could go on with dozens of additional programs in every one of our groups, but suffice to say we're executing on the strongest pipeline in Medtronic's nearly 70 years history. But international growth continues to grow well, you saw that in our results, and we expect that strong international growth to continue. Even better, Enviva has been paying out regular dividends for the past 5 years.Covering this stock for Raymond James is analyst Pavel Molchanov, who rates EVA as Outperform (i.e. Next question please Laurie. And so it's mostly impacting, right now, our MITG and RTG businesses. And one of them has been the ability for during this time our leadership team to sit down together. And in our coronary business, our Resolute Onyx Drug Eluting Stent became the first and only stent to receive CE Mark for one month DAPT treatment, for high bleeding risk patients. But I think that's increased over the last couple of months, as people realized what a -- how much the mission means, but we still have work to do. But because we found new ways, we're moving faster. In our cardiac and vascular group, we grew 1.3% this quarter, which was in line with our expectations. So I'm looking for bright spots coming out of COVID. Michael Coyle -- Executive Vice President, Group President-Cardiac and Vascular Group. Our Micra, which I've talked about a lot before, is a disruptive technology. But -- and you just guided us to 5.5% to 6% for the second quarter. And then also InterStim II, which is our -- that's our -- so MicroStim is our rechargeable platform. Thanks, Omar. On the bottom line at recent rates, the second quarter headwind should be similar to the first, and the full year has improved by about a nickel from the $0.20 impact, I mentioned last quarter. And while it sounded like a bit of a one-off, I just wanted to make sure we got your opinion on the subject and the outlook for growth in China for your business. When the current low interest rate regime is considered – the US Fed has set rates near zero, and Treasury bonds are yielding below 1% – NTB’s payment looks even better.Raymond James Donald Worthington, 4-star analyst with Raymond James, writes of Butterfield, “…robust capital levels [provide] more than sufficient loss absorption capacity in our view for whatever credit issues may arise. And then the final one that your question touches on, which really was a program that started in Q1 of this year is where we take certain in-warranty patients who have an Animas pump and we upgrade them to a Medtronic pump.